| BMU | basic metabolic unit; basic multicellular unit |
|---|---|
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| PM | after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr... |
| BP | Bachelor of Pharmacy; back pressure; barometric pressure; basic protein; bathroom privileges; bed pa... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| basic personality | See: basic personality type. (05 Mar 2000) |
|---|---|
| basic personality type | An individual's unique, covert, or underlying personality propensities, whether or not they are behaviourally manifest or overt, personality characteristics of an individual which are also shared by a majority of the members of a social group. (05 Mar 2000) |
| basic proteins | Proteins that are rich in basic amino acids; e.g., histones. (05 Mar 2000) |
| basic reaction | Any test by which an alkaline reaction is recognised, such as the change of red litmus paper to blue, an excess of hydroxide ions over hydrogen ions in aqueous solution as indicated by a pH value greater than 7 (at 22캜). Compare: dissociation constant of water. Synonym: basic reaction. (05 Mar 2000) |
| basic reproductive rate, ratio | <epidemiology> See Reproductive Ratio. (05 Dec 1998) |
| basic salt | A salt in which there are one or more hydroxyl ions not replaced by the electronegative element of an acid; e.g., Fe(OH)2Cl. (05 Mar 2000) |
| basic stain | <technique> A dye in which the cation is the coloured component of the dye molecule that binds to anionic groups of nucleic acids (PO4≡) or acidic mucopolysaccharides (e.g., chondroitin sulfate). (05 Mar 2000) |
| myelin basic proteins | A group of 7 proteins produced from a single gene by alternate splicing found in central and peripheral nervous system myelin. The major basic protein (mbp) has long been of interest because it is the antigen, that, when injected into an animal, elicits a cellular immune response that produces the CNS autoimmune disease called experimental allergic encephalomyelitis (encephalomyelitis, allergic). In the peripheral nervous system, myelin basic protein 18.5 kD is often referred to as the p1 protein. (12 Dec 1998) |
| haematoxylin-malachite green-basic fuchsin stain | <technique> A stain for epoxy resin-extracted sections; semi-thick sections have their plastic dissolved out and the residual tissue is stained sequentially with the various dyes; nuclei and astrocytes are purplish-pink and myelin, lipid droplets, nucleoli, and oligodendrocytes are bright blue-green. (05 Mar 2000) |
| fibroblast growth factor, basic | A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro. (12 Dec 1998) |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |